288 related articles for article (PubMed ID: 26658520)
1. Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
Vanhaesebroeck B; Whitehead MA; Piñeiro R
J Mol Med (Berl); 2016 Jan; 94(1):5-11. PubMed ID: 26658520
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Stamatkin C; Ratermann KL; Overley CW; Black EP
Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
4. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?
Singh P; Dar MS; Dar MJ
FEBS Lett; 2016 Sep; 590(18):3071-82. PubMed ID: 27552098
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
6. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking.
Mellor P; Furber LA; Nyarko JN; Anderson DH
Biochem J; 2012 Jan; 441(1):23-37. PubMed ID: 22168437
[TBL] [Abstract][Full Text] [Related]
7. p110δ PI3K as a therapeutic target of solid tumours.
Xenou L; Papakonstanti EA
Clin Sci (Lond); 2020 Jun; 134(12):1377-1397. PubMed ID: 32556179
[TBL] [Abstract][Full Text] [Related]
8. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
9. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
10. PI3K signalling in inflammation.
Hawkins PT; Stephens LR
Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
[TBL] [Abstract][Full Text] [Related]
11. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Wojtalla A; Fischer B; Kotelevets N; Mauri FA; Sobek J; Rehrauer H; Wotzkow C; Tschan MP; Seckl MJ; Zangemeister-Wittke U; Arcaro A
Clin Cancer Res; 2013 Jan; 19(1):96-105. PubMed ID: 23172887
[TBL] [Abstract][Full Text] [Related]
12. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
Jude JA; Tirumurugaan KG; Kang BN; Panettieri RA; Walseth TF; Kannan MS
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):427-35. PubMed ID: 22556157
[TBL] [Abstract][Full Text] [Related]
13. Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.
Mavrommati I; Cisse O; Falasca M; Maffucci T
Sci Rep; 2016 Mar; 6():23277. PubMed ID: 26983806
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.
Tsolakos N; Durrant TN; Chessa T; Suire SM; Oxley D; Kulkarni S; Downward J; Perisic O; Williams RL; Stephens L; Hawkins PT
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12176-12181. PubMed ID: 30442661
[TBL] [Abstract][Full Text] [Related]
15. Class I PI3K Biology.
Aytenfisu TY; Campbell HM; Chakrabarti M; Amzel LM; Gabelli SB
Curr Top Microbiol Immunol; 2022; 436():3-49. PubMed ID: 36243838
[TBL] [Abstract][Full Text] [Related]
16. The Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function.
Aksoy E; Saveanu L; Manoury B
Front Immunol; 2018; 9():2574. PubMed ID: 30498491
[TBL] [Abstract][Full Text] [Related]
17. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase as a therapeutic target in angiogenic disease.
Wu W; Xia X; Tang L; Luo J; Xiong S; Ma G; Lei H
Exp Eye Res; 2023 Nov; 236():109646. PubMed ID: 37716399
[TBL] [Abstract][Full Text] [Related]
19. The Role of p110δ in the Development and Activation of B Lymphocytes.
Newman R; Turner M
Adv Exp Med Biol; 2015; 850():119-35. PubMed ID: 26324350
[TBL] [Abstract][Full Text] [Related]
20. Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
McPhail JA; Burke JE
Adv Exp Med Biol; 2020; 1274():203-222. PubMed ID: 32894512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
